Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke (NCT05486351) | Clinical Trial Compass
UnknownNot Applicable
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
France, Spain318 participantsStarted 2021-03-05
Plain-language summary
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy. Patients in which anticoagulante therapy is mantained will be compared to those in which it is interrupted, in terms of stroke or systemic embolism and haemorrhagic transformation.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ischemic stroke of less than 24 hours since beginning of symptoms or last seen normal
* Mayor cardioembolic source (atrial fibrilation or flutter, mechanical heart valve prosthesis, recient miocardic infarction, rheumatic mitral valve stenosis, dilated cardiomyopathy, atrial myxoma, left ventricular focal akynesia.
* Previous treatment with oral anticoagulants (vitamin K antagonists or direct oral anticoagulants), having received the last dose within the previous 24 hours. Treatment with intravenous or subcutaneos heparin is also valid.
* Age \>18 years-old
* Signed informed consent (by patient or representative)
Exclusion Criteria:
* History of Intracraneal or extracraneal haemorrhage that contraindicates anticoagulant therapy
* Patients treated with intravenous thrombolysis as a reperfusion therapy
* Intracraneal haemorrhage on initial CT scan
* Health status with a short survival prevision
* Patients in which a neurosurgery intervention could be indicated
* Child-bearing woman or in breast-feeding period.
What they're measuring
1
Ischemic stroke recurrence
Timeframe: 90 days
2
Symptomatic haemorrhagic transformation
Timeframe: 90 days
Trial details
NCT IDNCT05486351
SponsorInstituto de Investigación Hospital Universitario La Paz